AdvaMed Statement on President’s Reciprocal Tariff Pause
WASHINGTON – Today AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker:
“We are encouraged by the President’s announcement of a 90-day pause on reciprocal tariffs. This is an important decision that restores some short-term certainty to global markets, including the American medtech industry, which is number one globally.
“Moving forward, we will spend the next 90 days working with the President and his senior team to ensure the unique role of the medtech industry is protected, with the hope that the ultimate outcome is ‘zero for zero’ tariffs on medtech with all key trading partners.”
Related Reading
News / Coverage & Payment / Diagnostics / Digital Health / Government & Legislative Affairs
Bipartisan Health Tech Investment Act Will Enhance Patient Access to AI-Enabled Medical Devices
April 10, 2025
WASHINGTON – AdvaMed, the Medtech Association, today commended Senators Mike Rounds (R-SD) and Martin Heinrich (D-NM) for introducing the Health Tech Investment Act (S. 1399). This landmark bipartisan legislation will establish a stable reimbursement pathway for medical devices authorized by the U.S. Food & Drug Administration (FDA) that rely on artificial intelligence (AI) and machine learning (ML), also known as Algorithm-Based Healthcare Services (ABHS).
Resource / Coverage & Payment / Executive Orders / Global & Trade / Supply Chain / Tariff
Amendment To Reciprocal Tariffs and Updated Duties as Applied to Low-Value Imports from The People’s Republic of China
April 9, 2025
Details a sweeping tariff hike to 84% on Chinese imports and de minimis increases, aiming to protect U.S. economic and national security.
News / Government & Legislative Affairs / Tariff
AdvaMed, Nine Other Organizations Urge Tariff Exemption for Medical Products
April 7, 2025
Washington, D.C.– AdvaMed®, the Medtech Association, and nine additional organizations urged an exemption from tariffs for medical and dental supplies, equipment, and devices, citing concerns about increased costs resulting in supply chain disruptions.
News / Coverage & Payment / Government & Legislative Affairs / Regulatory Affairs
AdvaMed Congratulates Dr. Oz on his Confirmation as CMS Administrator
April 3, 2025
Washington, D.C.– AdvaMed®, the Medtech Association, today released the following statement from President and CEO Scott Whitaker on the U.S. Senate’s confirmation of Dr. Mehmet Oz to serve as Administrator of the U.S. Centers for Medicare and Medicaid Services.
News / Executive Orders / Government & Legislative Affairs / Tariff
AdvaMed® Statement on Today’s Tariff Announcement
April 2, 2025
Washington, D.C.– AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker:
“Our country is the birthplace of the medical device and technology industry and leads the world in innovation and production because U.S. policies promote innovation. We support any and every policy that allows us to maintain our position of global primacy in every aspect of medical innovation imaginable. We also fully support the President’s goal of moving as much manufacturing into the United States as possible.
Blog / Coverage & Payment / Diagnostics / Global & Trade / Government & Legislative Affairs / Regulatory Affairs / Small Business
AdvaMed®’s Medical Innovation Agenda for the 119th Congress
March 28, 2025
AdvaMed®’s medtech priorities for the 119th Congress highlight opportunities to address the most important issues facing patients and the medical technology industry today.
Government & Legislative Affairs
Emerging Policy Response Center
Get expert insights, key documents, and event details on trade and policy shifts.
Event / China / Executive Orders / Global & Trade / Government & Legislative Affairs / Supply Chain
Tariffs: Navigating Customs Origins Requirements for tariffs, USMCA exemptions and beyond (Members Only)
Now On Demand
Exclusive member webinar on tariffs, customs, USMCA rules of origin, and compliance strategies with expert Larry Friedman. Air Date April 4, 2025. Now On Demand!